These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 26883197)

  • 1. Induction of cancer testis antigen expression in circulating acute myeloid leukemia blasts following hypomethylating agent monotherapy.
    Srivastava P; Paluch BE; Matsuzaki J; James SR; Collamat-Lai G; Blagitko-Dorfs N; Ford LA; Naqash R; Lübbert M; Karpf AR; Nemeth MJ; Griffiths EA
    Oncotarget; 2016 Mar; 7(11):12840-56. PubMed ID: 26883197
    [TBL] [Abstract][Full Text] [Related]  

  • 2. NY-ESO-1 Vaccination in Combination with Decitabine Induces Antigen-Specific T-lymphocyte Responses in Patients with Myelodysplastic Syndrome.
    Griffiths EA; Srivastava P; Matsuzaki J; Brumberger Z; Wang ES; Kocent J; Miller A; Roloff GW; Wong HY; Paluch BE; Lutgen-Dunckley LG; Martens BL; Odunsi K; Karpf AR; Hourigan CS; Nemeth MJ
    Clin Cancer Res; 2018 Mar; 24(5):1019-1029. PubMed ID: 28947565
    [No Abstract]   [Full Text] [Related]  

  • 3. The DNA demethylating agent 5-aza-2'-deoxycytidine induces expression of NY-ESO-1 and other cancer/testis antigens in myeloid leukemia cells.
    Almstedt M; Blagitko-Dorfs N; Duque-Afonso J; Karbach J; Pfeifer D; Jäger E; Lübbert M
    Leuk Res; 2010 Jul; 34(7):899-905. PubMed ID: 20381863
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Decitabine enhances targeting of AML cells by NY-ESO-1-specific TCR-T cells and promotes the maintenance of effector function and the memory phenotype.
    Kang S; Wang L; Xu L; Wang R; Kang Q; Gao X; Yu L
    Oncogene; 2022 Oct; 41(42):4696-4708. PubMed ID: 36097193
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment with 5-Aza-2'-Deoxycytidine Induces Expression of NY-ESO-1 and Facilitates Cytotoxic T Lymphocyte-Mediated Tumor Cell Killing.
    Klar AS; Gopinadh J; Kleber S; Wadle A; Renner C
    PLoS One; 2015; 10(10):e0139221. PubMed ID: 26447882
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunomodulatory action of the DNA methyltransferase inhibitor SGI-110 in epithelial ovarian cancer cells and xenografts.
    Srivastava P; Paluch BE; Matsuzaki J; James SR; Collamat-Lai G; Taverna P; Karpf AR; Griffiths EA
    Epigenetics; 2015; 10(3):237-46. PubMed ID: 25793777
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The DNA demethylating agent 5-aza-2'-deoxycytidine activates NY-ESO-1 antigenicity in orthotopic human glioma.
    Natsume A; Wakabayashi T; Tsujimura K; Shimato S; Ito M; Kuzushima K; Kondo Y; Sekido Y; Kawatsura H; Narita Y; Yoshida J
    Int J Cancer; 2008 Jun; 122(11):2542-53. PubMed ID: 18240144
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunomodulatory action of SGI-110, a hypomethylating agent, in acute myeloid leukemia cells and xenografts.
    Srivastava P; Paluch BE; Matsuzaki J; James SR; Collamat-Lai G; Karbach J; Nemeth MJ; Taverna P; Karpf AR; Griffiths EA
    Leuk Res; 2014 Nov; 38(11):1332-41. PubMed ID: 25260825
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epigenetic potentiation of NY-ESO-1 vaccine therapy in human ovarian cancer.
    Odunsi K; Matsuzaki J; James SR; Mhawech-Fauceglia P; Tsuji T; Miller A; Zhang W; Akers SN; Griffiths EA; Miliotto A; Beck A; Batt CA; Ritter G; Lele S; Gnjatic S; Karpf AR
    Cancer Immunol Res; 2014 Jan; 2(1):37-49. PubMed ID: 24535937
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MAGE-A1, MAGE-A3, and NY-ESO-1 can be upregulated on neuroblastoma cells to facilitate cytotoxic T lymphocyte-mediated tumor cell killing.
    Bao L; Dunham K; Lucas K
    Cancer Immunol Immunother; 2011 Sep; 60(9):1299-307. PubMed ID: 21626030
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epigenetic modulation to enable antigen-specific T-cell therapy of colorectal cancer.
    Chou J; Voong LN; Mortales CL; Towlerton AM; Pollack SM; Chen X; Yee C; Robbins PF; Warren EH
    J Immunother; 2012; 35(2):131-41. PubMed ID: 22306901
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synergistic induction of NY-ESO-1 antigen expression by a novel histone deacetylase inhibitor, valproic acid, with 5-aza-2'-deoxycytidine in glioma cells.
    Oi S; Natsume A; Ito M; Kondo Y; Shimato S; Maeda Y; Saito K; Wakabayashi T
    J Neurooncol; 2009 Mar; 92(1):15-22. PubMed ID: 19030781
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hypomethylating Agents and Immunotherapy: Therapeutic Synergism in Acute Myeloid Leukemia and Myelodysplastic Syndromes.
    Wong KK; Hassan R; Yaacob NS
    Front Oncol; 2021; 11():624742. PubMed ID: 33718188
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Decitabine immunosensitizes human gliomas to NY-ESO-1 specific T lymphocyte targeting through the Fas/Fas ligand pathway.
    Konkankit VV; Kim W; Koya RC; Eskin A; Dam MA; Nelson S; Ribas A; Liau LM; Prins RM
    J Transl Med; 2011 Nov; 9():192. PubMed ID: 22060015
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A potential role for immunotherapy in thyroid cancer by enhancing NY-ESO-1 cancer antigen expression.
    Gunda V; Frederick DT; Bernasconi MJ; Wargo JA; Parangi S
    Thyroid; 2014 Aug; 24(8):1241-50. PubMed ID: 24811699
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hypomethylating agents reactivate FOXO3A in acute myeloid leukemia.
    Thépot S; Lainey E; Cluzeau T; Sébert M; Leroy C; Adès L; Tailler M; Galluzzi L; Baran-Marszak F; Roudot H; Eclache V; Gardin C; de Botton S; Auberger P; Fenaux P; Kroemer G; Boehrer S
    Cell Cycle; 2011 Jul; 10(14):2323-30. PubMed ID: 21654193
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunotherapy of Myelodysplastic Syndrome: You Can Run, but You Can't Hide.
    Fuchs EJ
    Clin Cancer Res; 2018 Mar; 24(5):991-993. PubMed ID: 29284705
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NYESO-1/LAGE-1s and PRAME are targets for antigen specific T cells in chondrosarcoma following treatment with 5-Aza-2-deoxycitabine.
    Pollack SM; Li Y; Blaisdell MJ; Farrar EA; Chou J; Hoch BL; Loggers ET; Rodler E; Eary JF; Conrad EU; Jones RL; Yee C
    PLoS One; 2012; 7(2):e32165. PubMed ID: 22384167
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of systemic adoptive transfer immunotherapy targeting NY-ESO-1 for glioblastoma.
    Everson RG; Antonios JP; Lisiero DN; Soto H; Scharnweber R; Garrett MC; Yong WH; Li N; Li G; Kruse CA; Liau LM; Prins RM
    Neuro Oncol; 2016 Mar; 18(3):368-78. PubMed ID: 26330563
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased PRAME-specific CTL killing of acute myeloid leukemia cells by either a novel histone deacetylase inhibitor chidamide alone or combined treatment with decitabine.
    Yao Y; Zhou J; Wang L; Gao X; Ning Q; Jiang M; Wang J; Wang L; Yu L
    PLoS One; 2013; 8(8):e70522. PubMed ID: 23940586
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.